Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
| Autor: | Elizabeth M. Black, Yoon Ki Joo, Lilian Kabeche |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Biochemical Journal. 479:2345-2349 |
| ISSN: | 1470-8728 0264-6021 |
| DOI: | 10.1042/bcj20220461 |
| Popis: | Chk1 is a member of the DNA damage response pathway, whose loss leads to replication stress and genome instability. Because of its protective role against lethal levels of DNA replication stress, Chk1 has been studied as a valuable and intriguing target for cancer therapy. However, one of the most prominent challenges with this strategy is development of resistance to Chk1 inhibitors, rendering the treatment ineffective. In their recent papers, Hunter and colleagues demonstrate multiple mechanisms by which Chk1 inhibitor resistance can arise in lymphomas. Specifically, this series of papers identify the relationship between dysfunction in NF-κB and the development of Chk1 inhibitor resistance through a loss of Chk1 activity in mouse models of lymphoma. They identify that cells lacking Chk1 activity can compensate for this loss through up-regulation of alternative pathways, such as PI3K/AKT. Finally, this work also identifies a novel role for Claspin, an important Chk1 activator, in female fertility and cancer development, furthering our understanding of how dysfunction in the Claspin/Chk1 signaling pathway affects disease states. These findings improve our understanding of drug resistance in cancer therapy, which has important implications for clinical use of Chk1 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|